Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

482 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer.
Okuno K, Kandimalla R, Mendiola M, Balaguer F, Bujanda L, Fernandez-Martos C, Aparicio J, Feliu J, Tokunaga M, Kinugasa Y, Maurel J, Goel A. Okuno K, et al. Among authors: feliu j. Mol Cancer. 2023 Jan 20;22(1):13. doi: 10.1186/s12943-022-01699-2. Mol Cancer. 2023. PMID: 36670412 Free PMC article. No abstract available.
Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Feliu J, González Barón M, García-Girón C, Espinosa E, García-Alfonso P, Belón J, Blanco E, Garrido P, Ordónez A, Gómez-Navarro J, Zamora P. Feliu J, et al. Cancer. 1996 Jul 15;78(2):211-6. doi: 10.1002/(SICI)1097-0142(19960715)78:2<211::AID-CNCR4>3.0.CO;2-O. Cancer. 1996. PMID: 8673994 Clinical Trial.
Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group.
Feliu J, González Barón M, Espinosa E, García Girón C, de la Gándara I, Espinosa J, Colmenarejo A, Jalón JI, Fernández Y, de Castro J. Feliu J, et al. Cancer. 1997 May 15;79(10):1884-9. doi: 10.1002/(sici)1097-0142(19970515)79:10<1884::aid-cncr7>3.0.co;2-g. Cancer. 1997. PMID: 9149013
Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer.
Feliu J, Vicent JM, García-Girón C, Constela M, Fonseca E, Aparicio J, Lomas M, Antón-Aparicio L, Dorta FJ, Gonzalez-Baron M; Oncopaz Cooperative Group and Associated Hospitals. Feliu J, et al. Br J Cancer. 2004 Nov 15;91(10):1758-62. doi: 10.1038/sj.bjc.6602217. Br J Cancer. 2004. PMID: 15505621 Free PMC article. Clinical Trial.
Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer.
Feliu J, Castañón C, Salud A, Mel JR, Escudero P, Pelegrín A, López-Gómez L, Ruiz M, González E, Juárez F, Lizón J, Castro J, González-Barón M; Oncopaz Cooperative Group, Spain. Feliu J, et al. Br J Cancer. 2005 Nov 28;93(11):1230-5. doi: 10.1038/sj.bjc.6602860. Br J Cancer. 2005. PMID: 16265344 Free PMC article. Clinical Trial.
482 results